A meta-analysis including several anti-VEGF drugs (axitinib, cediranib, pazopanib, ramucirumab sorafenib, sunitinib, and vandetanib), including 10553 patients from 36 clinical trials showed an incidence of all- and high-grade HF of 3.2% (OR = 2.37, 95% CI 1.76–3.20) and 1.4% (OR = 3.51, 95% CI 1.74–7.05), respectively. Here, VEGFA is linked to hydrops fetalis.